BackgroundThe prevalence of hypertension (HTN) is higher in patients with non-alcoholic fatty liver disease (NAFLD). Inflammation is the key link between HTN and NAFLD. Systemic inflammation can be dramatically increased by inflammatory diet intake. However, whether controlling the inflammatory diet intake in NAFLD patients could affect the occurrence of HTN still remains unknown. Our aim… Continue reading Association between dietary inflammation index and hypertension in participants with different degrees of liver steatosis
Tag: hepatic-steatosis
Non-heavy alcohol use associates with liver fibrosis and ‘nonalcoholic’ steatohepatitis in the Framingham Heart Study
Background and AimsWhile heavy alcohol use consistently associates with liver disease, the effects of non-heavy alcohol consumption are less understood. We aimed to investigate the relationship between non-heavy alcohol use and chronic liver disease.MethodsThis cross-sectional study included 2629 current drinkers in the Framingham Heart Study who completed alcohol use questionnaires and transient elastography. We defined… Continue reading Non-heavy alcohol use associates with liver fibrosis and ‘nonalcoholic’ steatohepatitis in the Framingham Heart Study
EDP-305 in patients with #NASH: A phase II double-blind placebo-controlled dose-ranging study
•EDP-305 is an oral farnesoid X receptor (FXR) agonist being developed to treat nonalcoholic steatohepatitis (NASH).•In a randomized, placebo-controlled study, 12-week study, EDP-305 reduced ALT levels and MRI-PDFF•These results support further development of EDP-305 in patients with NASH with longer term studies. ABSTRACTBackground & AimsEDP-305 is an oral farnesoid X receptor (FXR) agonist under development… Continue reading EDP-305 in patients with #NASH: A phase II double-blind placebo-controlled dose-ranging study
Hepatic #Histopathology Among Excessive #Drinkers Without Advanced Liver Disease
Alcohol-associated liver disease represents a spectrum of histopathological changes from steatosis to advanced fibrosis and cirrhosis. The major goals of this retrospective study were to characterize the histologic features in patients with excessive alcohol use who presented with an abnormal hepatic panel and/or abnormal radiographic imaging and did not meet the clinical diagnosis of alcoholic… Continue reading Hepatic #Histopathology Among Excessive #Drinkers Without Advanced Liver Disease
Efficacy and safety of #linagliptin in type 2 #diabetes patients with self-reported #hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials
Liver disease is highly prevalent among people with type 2 diabetes mellitus (T2DM). We evaluated the dipeptidyl peptidase-4 inhibitor linagliptin in subjects with T2DM and hepatic disorders.. ..Of the 7009 participants (56% white, 39% Asian), 574 had hepatic disorders, most commonly hepatic steatosis (60%). At week 24, adjusted mean ± standard error (SE) change in… Continue reading Efficacy and safety of #linagliptin in type 2 #diabetes patients with self-reported #hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials
Advanced #Liver Fibrosis Is Common in Patients With Type 2 #Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Assess the prevalence of nonalcoholic fatty liver disease (NAFLD) and of liver fibrosis associated with nonalcoholic steatohepatitis in unselected patients with type 2 diabetes mellitus (T2DM). A total of 561 patients with T2DM (age: 60 ± 11 years; BMI: 33.4 ± 6.2 kg/m2; and HbA1c: 7.5 ± 1.8%) attending primary care or endocrinology outpatient clinics… Continue reading Advanced #Liver Fibrosis Is Common in Patients With Type 2 #Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
A Placebo-Controlled Trial of Subcutaneous #Semaglutide in Nonalcoholic #Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited. The efficacy and safety of the glucagon-like peptide-1 receptor agonist semaglutide in patients with NASH is not known.. ..In total, 320 patients (of whom 230 had stage F2 or F3 fibrosis) were randomly assigned to… Continue reading A Placebo-Controlled Trial of Subcutaneous #Semaglutide in Nonalcoholic #Steatohepatitis
The #triglyceride- #glucose index is associated with the severity of hepatic #steatosis and the presence of liver #fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults
The triglyceride-glucose index (TyG) is a reliable predictor of non-alcoholic fatty liver disease (NAFLD). Its association with the severity of hepatic steatosis and liver fibrosis in NAFLD is poorly understood. This study evaluated the relationship between these factors in NAFLD. ..The TyG index was significantly correlated with the severity of hepatic steatosis and the presence… Continue reading The #triglyceride- #glucose index is associated with the severity of hepatic #steatosis and the presence of liver #fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults
Association of Hepatic #Steatosis with Major Adverse Cardiovascular Events, Independent of #Coronary Artery Disease
Hepatic steatosis has been associated with increased risk of major adverse cardiovascular events (MACE) but it is not clear whether steatosis is independently associated with risk of MACE. We investigated whether steatosis is associated with risk of MACE independently of the presence and extent of baseline coronary artery disease, assessed by comprehensive contrast-enhanced computed tomography… Continue reading Association of Hepatic #Steatosis with Major Adverse Cardiovascular Events, Independent of #Coronary Artery Disease
2 Medical News 